|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0020823,
umls-concept:C0031928,
umls-concept:C0040808,
umls-concept:C0045093,
umls-concept:C0069717,
umls-concept:C0185112,
umls-concept:C0205269,
umls-concept:C0393022,
umls-concept:C0442967,
umls-concept:C1274040,
umls-concept:C1332225,
umls-concept:C1704419
|
|
pubmed:dateCreated |
2006-5-16
|
|
pubmed:abstractText |
The prognosis of patients with aggressive non-Hodgkin's lymphoma (NHL) relapsing or progressing after front-line therapy remains poor. Since high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) can cure a proportion of such patients, provided that a substantial tumor shrinkage is achieved, the development of more effective and less toxic salvage regimens remains a major challenge. We evaluated the clinical activity, toxicity and mobilizing capacity of a new salvage regimen, which combines gemcitabine and oxaliplatin with ifosfamide and rituximab (R-GIFOX) in patients with relapsed and refractory CD20(+) NHL.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17 Suppl 4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
iv18-24
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16702180-Adolescent,
pubmed-meshheading:16702180-Adult,
pubmed-meshheading:16702180-Aged,
pubmed-meshheading:16702180-Antibodies, Monoclonal,
pubmed-meshheading:16702180-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:16702180-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16702180-Combined Modality Therapy,
pubmed-meshheading:16702180-Deoxycytidine,
pubmed-meshheading:16702180-Disease-Free Survival,
pubmed-meshheading:16702180-Female,
pubmed-meshheading:16702180-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:16702180-Humans,
pubmed-meshheading:16702180-Ifosfamide,
pubmed-meshheading:16702180-Lymphoma, B-Cell,
pubmed-meshheading:16702180-Lymphoma, Follicular,
pubmed-meshheading:16702180-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:16702180-Lymphoma, Mantle-Cell,
pubmed-meshheading:16702180-Male,
pubmed-meshheading:16702180-Middle Aged,
pubmed-meshheading:16702180-Neoplasm Recurrence, Local,
pubmed-meshheading:16702180-Organoplatinum Compounds,
pubmed-meshheading:16702180-Pilot Projects,
pubmed-meshheading:16702180-Remission Induction,
pubmed-meshheading:16702180-Salvage Therapy,
pubmed-meshheading:16702180-Stem Cell Transplantation,
pubmed-meshheading:16702180-Survival Rate,
pubmed-meshheading:16702180-Transplantation, Autologous,
pubmed-meshheading:16702180-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
|
|
pubmed:affiliation |
Hematology-Oncology Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, Naples, Italy.
|
|
pubmed:publicationType |
Journal Article
|
